Pandemic Preparedness: Can Genomic Surveillance Flag

How does genomic surveillance support pandemic preparedness?

Early detection was a central concern in the pandemic preparedness appeal published by WHO on March 20, 2024. The appeal called for stronger capacity to identify dangerous pathogens and share information that could support tests, treatments and vaccines. Its publication date matters: it provides background to the preparedness debate, rather than evidence of a new announcement in October 2026. One practical scientific component of that agenda is genomic surveillance. [WHO pandemic preparedness appeal](https://www.who.int/news/item/20-03-2024-call-for-urgent-agreement-on-international-deal-to-prepare-for-and-prevent-future-pandemics).

Sequencing reveals the genetic instructions carried by a virus, bacterium or other pathogen. Comparing sequences collected across places and times can help researchers investigate relationships between infections and recognize changes that warrant further study. WHO's global strategy for 2022–2032 places this work within a broader system encompassing sample collection, diagnostic testing, analysis and information sharing. The practical implication is that a sequencing machine becomes useful for preparedness when its findings reach people who can investigate and respond. [WHO genomic surveillance strategy](https://www.who.int/publications-detail-redirect/9789240046979).

Can a new mutation reveal how dangerous a virus will be?

Viruses change as they circulate. WHO explains that most genetic changes have little or no effect on their properties, while some can influence transmission, disease severity or the performance of vaccines, medicines and diagnostic tests. Finding an unfamiliar mutation therefore creates a research question; it does not automatically establish a new health emergency. Researchers must examine whether the genetic change produces a meaningful biological effect and whether that effect appears in people. [WHO explanation of variant tracking](https://www.who.int/activities/tracking-SARS-CoV-2-variants/).

For example, an apparent increase in hospitalizations alongside a new variant requires careful investigation. Researchers need to consider patients' ages, underlying conditions, vaccination histories and previous infections before attributing the increase to the virus itself. Laboratory studies can explore changes in antibody recognition, while linked clinical and surveillance data help assess consequences for patients. WHO's variant surveillance guidance describes this combination of laboratory, epidemiological and clinical assessment. The distinction helps prevent both exaggerated alarm and premature reassurance. [WHO guidance for surveillance of SARS-CoV-2 variants](https://iris.who.int/bitstream/handle/10665/343775/WHO-2019-nCoV-surveillance-variants-2021.1-eng.pdf).

What must health systems improve before the next outbreak?

Sequencing capacity expanded substantially during the COVID-19 era. A 2024 paper in Frontiers in Public Health reported that the number of countries with next-generation sequencing capacity rose from 103 in February 2021 to 167 in December 2023, out of 194 assessed. These are historical capacity figures, not a current measure of surveillance quality. The paper also identified financing as a major challenge and described a costing tool intended to help laboratories budget for sustainable operations. [Akande and colleagues, Frontiers in Public Health](https://pmc.ncbi.nlm.nih.gov/articles/PMC11111868/).

WHO's March 2026 framework for national public health agencies places laboratory and diagnostic systems alongside surveillance, emergency coordination, workforce development and communication. Applied to genomics, the implication is that readiness must extend across the entire response: samples need to reach laboratories, results need interpretation, and responsible teams need the resources to act. An instrument count cannot show whether those connections work. Preparedness assessments should therefore examine operational performance and gaps in access, alongside technical capacity. [WHO and IANPHI preparedness framework](https://pandemichub.who.int/publications/i/item/framework-for-health-emergency-preparedness-and-response-capabilities-for-national-public-health-agencies).